Dr. Daniel J. Mckeone

Dr. Ramdas is a fellowship-trained specialist in pediatric hematology/oncology and board certified in pediatrics. His clinical interests include general pediatric hematology and oncology; childhood cancer (e.g., leukemia, lymphoma, brain tumor, neuroblastoma, Wilms' tumor, bone tumor, soft tissue sarcoma); and pediatric hematology (e.g., anemia, thrombocytopenia, neutropenia, bone marrow failure, sickle cell disease, bleeding disorders, ITP). Dr. Ramdas earned his medical degree from Calcutta National Medical College in India. He then moved to the United States to complete his residency and a fellowship in pediatric hematology and oncology at Louisiana State University. Dr. Ramdas is certified by the American Board of Pediatrics in pediatrics and in pediatric hematology-oncology. Dr. Ramdas is rated as an Advanced provider by MediFind in the treatment of Langerhans Cell Histiocytosis. His top areas of expertise are Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, Hepatoblastoma, and Bone Marrow Aspiration.

Girmay Tekle-Yohannes, MD, is a board-certified pediatric hematologist oncologist. He treats pediatric cancers, including solid tumors and leukemia, and other blood conditions such as anemia, leukopenia, thrombocytopenia, pancytopenia, bleeding disorders and blood clotting disorders. He performs specialized procedures, including bone marrow aspiration, bone marrow biopsy, spinal tap and intrathecal administration of chemotherapy.|Dr. Tekle-Yohannes earned his medical degree from Jimma University in Jimma, Ethiopia. He followed that with residencies at Ethio-Swedish Children’s Hospital/Black Lion Hospital in Addis Ababa, Ethiopia, and Newark Beth Israel Medical Center/Children’s Hospital of New Jersey. After his residencies, he completed a fellowship in pediatric hematology and oncology at Cleveland Clinic Children’s Hospital.|A young child he met during his residency inspired him to practice in his specialty. “That child was exceptionally resilient,” he says. “Their family sold their house to purchase chemotherapy from abroad during a time of drug shortage.”|“The Children’s Oncology Group further consolidated my interest,” he notes. “They developed evidence-based and protocol-based cancer therapy and conducted multi-institution cooperative research that resulted in improvement of childhood cancer survival.”|Dr. Tekle-Yohannes is an accomplished researcher and presenter. He also serves as a clinical assistant professor of pediatrics at Geisinger Commonwealth School of Medicine in Scranton.|He's an active member of several professional organizations and societies, including The American Society of Pediatric Hematology/Oncology, Children’s Oncology Group, American Academy of Pediatrics and American Society of Hematology. Dr. Tekle is rated as an Experienced provider by MediFind in the treatment of Langerhans Cell Histiocytosis. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Langerhans Cell Histiocytosis, Neurofibromatosis Type 1 (NF1), and Immune Thrombocytopenic Purpura (ITP).